Tumores neuroendocrinos: la era de las terapias dirigidas |
| |
| Authors: | Jaume Capdevila Guillem Argilés Nuria Mulet-Margalef Josep Tabernero |
| |
| Institution: | 1. Servicio de Dermatología, Hospital Santiago Apóstol, Vitoria, España;2. Servicio de Anatomía Patológica, Hospital Santiago Apóstol, Vitoria, España;1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Section of Interventional Endoscopy, Indiana University School of Medicine, Indianapolis, IN, United States;2. Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States;1. Istanbul University, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Turkey;2. Istanbul Ba?c?lar Training and Education Hospital, Department of Nuclear Medicine, Istanbul, Turkey;3. Y?ld?r?m Beyaz?t University Hospital, Department of Nuclear Medicine, Ankara, Turkey |
| |
| Abstract: | Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the second most prevalent group of advanced gastrointestinal tract tumors. Resources invested in research on this patient population have exponentially increased in recent years, and this has become one of the most attractive fields for oncological research. Several proangiogenic proteins have been found to be overexpressed in GEP-NETs, including vascular endothelial growth factor and its receptors and the more closely related intracellular signaling pathways such as the epidermal growth factor pathway, type I insulin-like growth factor receptor, and the PI3K-(PTEN)-AKT-mTOR pathway. The recent results of the three most important Phase III studies in GEP-NETs have allowed for approval of two targeted agents, sunitinib and everolimus, for the treatment of patients with pancreatic neuroendocrine tumors after decades of minimal advances in this population. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
